Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
Jacobio Pharma poised to turn a profit from precision cancer drugs
The Chinese firm is pocketing an upfront payment for a gene-focused drug under development and anticipates rising sales of an approved treatment for lung cancer Key Takeaways: Early clinical data…
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
After months of rumors drove up its share price, the Chinese drug company has unveiled a record licensing deal with AstraZeneca, only to see its stock tumble Key Takeaways: Going…
Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Recent Articles
RELATED ARTICLES
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK -
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Insilico revenue soars above $100 million on AI drug partnerships
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
